MX2012009768A - Metodos y composiciones para aumentar la supervivencia del injerto de grasa. - Google Patents

Metodos y composiciones para aumentar la supervivencia del injerto de grasa.

Info

Publication number
MX2012009768A
MX2012009768A MX2012009768A MX2012009768A MX2012009768A MX 2012009768 A MX2012009768 A MX 2012009768A MX 2012009768 A MX2012009768 A MX 2012009768A MX 2012009768 A MX2012009768 A MX 2012009768A MX 2012009768 A MX2012009768 A MX 2012009768A
Authority
MX
Mexico
Prior art keywords
fat
epo
erythropoietin
cells
treated
Prior art date
Application number
MX2012009768A
Other languages
English (en)
Spanish (es)
Inventor
Saher Hamed
Original Assignee
Sebana Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sebana Medical Ltd filed Critical Sebana Medical Ltd
Publication of MX2012009768A publication Critical patent/MX2012009768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
MX2012009768A 2010-02-23 2011-02-23 Metodos y composiciones para aumentar la supervivencia del injerto de grasa. MX2012009768A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30699110P 2010-02-23 2010-02-23
PCT/IL2011/000181 WO2011104707A1 (en) 2010-02-23 2011-02-23 Methods and compositions for enhancing fat graft survival

Publications (1)

Publication Number Publication Date
MX2012009768A true MX2012009768A (es) 2013-02-27

Family

ID=44506187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009768A MX2012009768A (es) 2010-02-23 2011-02-23 Metodos y composiciones para aumentar la supervivencia del injerto de grasa.

Country Status (12)

Country Link
US (1) US20120315254A1 (enExample)
EP (1) EP2539443B1 (enExample)
JP (2) JP5823986B2 (enExample)
CN (1) CN102906250A (enExample)
AU (1) AU2011219425A1 (enExample)
BR (1) BR112012021179A2 (enExample)
CA (1) CA2790867A1 (enExample)
IL (1) IL221619A (enExample)
IN (1) IN2012MN02218A (enExample)
MX (1) MX2012009768A (enExample)
RU (1) RU2012140379A (enExample)
WO (1) WO2011104707A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012021179A2 (pt) * 2010-02-23 2015-09-15 Sebana Medical Ltd método para aprimorar a sobrevivência da gordura adiposa em um paciente que necessite da mesma, uso de eritropoietina e composição farmacêutica
JP5953035B2 (ja) * 2011-11-28 2016-07-13 学校法人慶應義塾 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム
CN107456606A (zh) * 2017-08-30 2017-12-12 上海新肌生物科技有限公司 一种脂肪细胞存活率提高91%的复活素配方及制备方法
CN110229785A (zh) * 2019-06-17 2019-09-13 白晋 一种利用血管内皮祖细胞提升脂肪移植成功率的方法
CN111548988B (zh) * 2020-05-14 2023-06-20 江苏芝海生物科技有限公司 一种医用漂洗液及其制备方法和应用
CA3200227A1 (en) * 2020-11-25 2022-06-02 Alexandra Sophie DE BOER Adipogenic cell compositions and methods
CN113413177B (zh) * 2021-06-23 2022-08-02 美闺(长沙)医疗美容有限公司 一种保持自体脂肪活性的移植设备及控制方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US7651684B2 (en) * 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
CN101415451A (zh) * 2003-06-18 2009-04-22 马克罗珀尔生物外科公司 在加大自体脂肪转移时使用来自脂肪组织的细胞的方法
ES2346226T3 (es) * 2003-12-30 2010-10-13 Augustinus Bader Uso de la eritropoyetina para la regeneracion de tejido hepatico.
ITPD20050168A1 (it) * 2005-06-01 2006-12-02 Fidia Advanced Biopolymers Srl Formulazioni di acido lipoico ed acido ialuronico e o suoi derivati e loro impiego in campo farmaceutico e cosmetico
WO2007087402A2 (en) * 2006-01-24 2007-08-02 Brown University Cell aggregation and encapsulation device and method
WO2008019434A1 (en) 2006-08-14 2008-02-21 Victorian Tissue Engineering Pty Ltd The use of growth factors in a method of improving fat-graft survival
US20110123481A1 (en) * 2007-08-16 2011-05-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
BR112012021179A2 (pt) * 2010-02-23 2015-09-15 Sebana Medical Ltd método para aprimorar a sobrevivência da gordura adiposa em um paciente que necessite da mesma, uso de eritropoietina e composição farmacêutica

Also Published As

Publication number Publication date
EP2539443A1 (en) 2013-01-02
CA2790867A1 (en) 2011-09-01
IN2012MN02218A (enExample) 2015-06-12
IL221619A (en) 2017-09-28
RU2012140379A (ru) 2014-03-27
US20120315254A1 (en) 2012-12-13
EP2539443A4 (en) 2013-12-11
JP6023864B2 (ja) 2016-11-09
JP5823986B2 (ja) 2015-11-25
AU2011219425A1 (en) 2012-10-18
EP2539443B1 (en) 2019-03-27
JP2016041261A (ja) 2016-03-31
WO2011104707A1 (en) 2011-09-01
JP2013520271A (ja) 2013-06-06
BR112012021179A2 (pt) 2015-09-15
CN102906250A (zh) 2013-01-30

Similar Documents

Publication Publication Date Title
JP6023864B2 (ja) 脂肪移植物の生存を増大させるための方法及び組成物
Xu et al. RETRACTED: Exosomes derived from adipose tissue, bone marrow, and umbilical cord blood for cardioprotection after myocardial infarction
KR101738323B1 (ko) 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
CA2592840C (en) Adipose-derived stem cells for tissue regeneration and wound healing
TW202034932A (zh) 間質幹細胞之胞外泌體及其用途
WO2015004609A2 (en) Adherent cells from placenta and use thereof in treatment of injured tendons
Tracy et al. State of the field: cellular and exosomal therapeutic approaches in vascular regeneration
Ikhapoh et al. Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells
CN105377275B (zh) 用于静脉给药的干细胞组合物
Zhang et al. PFKFB3-mediated glycometabolism reprogramming modulates endothelial differentiation and angiogenic capacity of placenta-derived mesenchymal stem cells
CN113038966A (zh) 调节软骨细胞增殖和增加软骨基质生成的组合物和方法
KR101816964B1 (ko) 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
WO2012025925A1 (en) Methods of improving transplantation using sdf-1alpha
KR101132858B1 (ko) 내피전구세포의 체외 증폭방법
KR20250037691A (ko) 중간엽 줄기세포 스페로이드, 이의 제조방법 및 이를 포함하는 조성물
El-Qashty et al. The role of erythropoietin-loaded hydrogel versus adipose derived stem cell secretome in the regeneration of tongue defects
Supanc et al. Traumatized muscle‐derived multipotent progenitor cells recruit endothelial cells through vascular endothelial growth factor‐A action
Burdzińska et al. Sodium ascorbate and basic fibroblast growth factor protect muscle-derived cells from H2O2-induced oxidative stress
JP2022522460A (ja) 間葉系幹細胞の血管新生能を改善する方法
Mahoney Composite Adipose Derived Delivery Systems for Soft Tissue Restoration
Sukpat et al. A low dose of simvastatin enhanced the therapeutic efficacy of mesenchymal stem cell (MSC) transplantation in skin wound healing in diabetic mice associated with increases in pAkt, SDF-1, and angiogenesis
Delecave Dias Effects Of Cell-Free Conditioned Media on Healing of Rat Achilles Tendon
Sava The development of a hydrogel-based regenerative therapy for brain tissue repair and functional recovery following ischaemic stroke
US20160296606A1 (en) Cellular Factor-Containing Solution Compositions for the Treatment of Rhinovirus Infection and Symptoms
Rezazadeh et al. The effect of bone marrow derived mesenchymal stem cells on the survival of random skin flap on sterptozotocin-induced diabetic rats

Legal Events

Date Code Title Description
FA Abandonment or withdrawal